O Desafio de Incorporar Tecnologias de Alto Custo: Uma Análise dos Inibidores de PCSK9

[1]  Rodrigo Gomes Vieira de Melo,et al.  Análise de Custo-Efetividade da Terapia com Evolocumabe em Pacientes com Alto Risco de Eventos Cardiovasculares no Contexto do SUS – Brasil , 2021, Arquivos Brasileiros de Cardiologia.

[2]  E. Braunwald.  How to live to 100 before developing clinical coronary artery disease: a suggestion. , 2021, European heart journal.

[3]  Y. Gong,et al.  Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials , 2020, Advances in Therapy.

[4]  M. Behzadifar,et al.  Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review , 2019, Heart Failure Reviews.

[5]  A. Conforto,et al.  The cost of stroke in a public hospital in Brazil: a one-year prospective study. , 2019, Arquivos de neuro-psiquiatria.

[6]  E. Moriguchi,et al.  PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice , 2019, Arquivos brasileiros de cardiologia.

[7]  E. Moriguchi,et al.  Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk , 2018, Arquivos brasileiros de cardiologia.

[8]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[9]  R. Dullaart.  PCSK9 Inhibition to Reduce Cardiovascular Events. , 2017, The New England journal of medicine.

[10]  V. Castilho,et al.  Coronary Artery Bypass Graft Surgery Cost Coverage by the Brazilian Unified Health System (SUS) , 2017, Brazilian journal of cardiovascular surgery.

[11]  DANBURY TRASH COMPANIES,et al.  Press releases , 2001, Heart Drug.